GYKI 53405

Synonyms: LY 293606
GYKI 53405 (LY 293606) 是一种非竞争性、具有口服活性的 AMPA 受体拮抗剂,对 GABAA、GABAB 或苯二氮䓬受体无显著结合亲和力,可增加自我梳理行为、诱发湿狗样抖动、降低自发活动、产生类抗焦虑行为、逆转 mCPP 诱导的致焦虑效应、抑制自主运动活动、抑制声音诱导和最大电休克诱导的癫痫发作、延长全脑缺血模型的生存期,并在低于镇静阈值的剂量下表现出持久的抗惊厥作用,可用于失神性癫痫、焦虑症和全脑缺血的相关研究。
产品编号: MS-M24304 CAS No.: 143691-37-6 分子式: C19H19N3O3 分子量: 337.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

GYKI 53405 (LY 293606) 是一种非竞争性、具有口服活性的 AMPA 受体拮抗剂,对 GABAA、GABAB 或苯二氮䓬受体无显著结合亲和力,可增加自我梳理行为、诱发湿狗样抖动、降低自发活动、产生类抗焦虑行为、逆转 mCPP 诱导的致焦虑效应、抑制自主运动活动、抑制声音诱导和最大电休克诱导的癫痫发作、延长全脑缺血模型的生存期,并在低于镇静阈值的剂量下表现出持久的抗惊厥作用,可用于失神性癫痫、焦虑症和全脑缺血的相关研究。

生物实验数据

生物活性 GYKI 53405 (LY 293606) is a non-competitive, orally active AMPA receptor antagonist that shows no significant binding affinity for GABAA, GABAB, or benzodiazepine receptors, and it increases self-grooming behavior, induces wet dog shakes, reduces spontaneous locomotor activity, produces anxiolytic-like behavior, reverses mCPP-induced anxiogenic effects, suppresses locomotor activity, inhibits sound-induced and maximal electroshock-induced seizures, prolongs survival in a global cerebral ischemia model, and exhibits long-lasting anticonvulsant effects at doses below the sedative threshold, making it useful for research on absence epilepsy, anxiety disorders, and global cerebral ischemia.
IC50 & Target

AMPA Receptor

 

体外研究
(In Vitro)

GYKI 53405 可抑制原代培养的 Sprague-Dawley 大鼠胚胎端脑细胞中红藻氨酸诱导的全细胞电流,其 IC50 为 7.4 μM。
GYKI 53405 可抑制雄性 Wistar 大鼠海马脑片 CA1 锥体细胞中 AMPA 受体介导的群峰电位幅度,其 IC50 为 17.8 μM。
GYKI 53405 (10-7 M) 在 10-7 M 浓度下对 GABAA、GABAB 或苯二氮䓬受体均无显著结合亲和力。

体内研究
(In Vivo)

GYKI 53405 (16 mg/kg;腹腔注射;单次) 无法显著改变遗传性失神癫痫 WAG/Rij 大鼠的棘波放电、觉醒状态,也不会诱导其产生不良神经行为。
GYKI 53405 (3 mg/kg;口服;单剂量) 可在高架十字迷宫实验中使雄性 Sprague-Dawley 大鼠产生类抗焦虑行为。
GYKI 53405 (3 mg/kg;腹腔注射;单次给药) 可逆转雄性 Wistar 大鼠在明暗箱实验中由 mCPP 诱导的焦虑样行为。
GYKI 53405 (口服) 对雄性 NMRI 小鼠产生镇静作用,ID50 为 9.8 mg/kg。
GYKI 53405 (腹腔注射;单次) 在听觉诱发惊厥易感 DBA/2j 小鼠中表现出强效抗惊厥活性,其抑制强直性伸展惊厥的 ED50 值为 1.1 mg/kg,抑制阵挛性惊厥的 ED50 值为 3.1 mg/kg。
GYKI 53405 (腹腔注射;单次;电休克前 30 分钟) 可抑制 NMRI 小鼠中最大电休克诱导的强直性后肢伸展发作,其腹腔注射 ED50 为 2.6 mg/kg。
GYKI 53405 (3.75-30 mg/kg;腹腔注射;单次;MgCl2 注射前 30 分钟) 在 NMRI 小鼠的 MgCl2 诱导全脑缺血模型中发挥剂量依赖性神经保护活性,其腹腔注射的 PD50 为 8.3 mg/kg,且从 7.5 mg/kg 剂量开始可显著延长小鼠存活时间。

Animal Model: WAG/Rij (male, 7-8 months old, 320-420 g, genetic absence epilepsy model)
Dosage: 16 mg/kg
Administration: i.p.; single dose
Result: Failed to significantly alter cumulative duration, number, or proportional occurrence of spike-wave discharges during light slow wave sleep compared to vehicle-treated controls.
Failed to significantly alter vigilance states (wakefulness, light slow wave sleep, deep slow wave sleep) compared to vehicle-treated controls.
Failed to significantly alter average paroxysm duration compared to vehicle-treated controls.
Increased frequency of self-grooming compared to vehicle-treated controls.
Induced wet dog shakes in 3 of 8 animals.
Slightly reduced locomotor activity compared to vehicle-treated controls.
Did not induce abnormal behavior or ataxia.
Animal Model: Sprague-Dawley (male, 220-250 g)
Dosage: 3 mg/kg
Administration: p.o.; single dose
Result: Significantly increased the time rats spent in the open arms of the elevated plus-maze.
Animal Model: Wistar (male, 180-220 g)
Dosage: 3 mg/kg
Administration: i.p.; single dose
Result: Significantly reversed the mCPP-induced reduction in movement time in the lit area of the light-dark box.
Animal Model: NMRI (male, 20-25 g)
Dosage: 1 mg/kg; 9.8 mg/kg
Administration: p.o.; single dose
Result: Defined the maximal non-sedating dose as 1 mg/kg p.o.
Produced sedative inhibition of spontaneous motor activity at doses above 1 mg/kg p.o., with an ID50 of 9.8 mg/kg p.o.
Animal Model: DBA/2j (male, 7-11 g, audiogenic seizure model)
Dosage: 1.1 mg/kg (tonic extensor seizure inhibition); 3.1 mg/kg (clonic seizure inhibition); 5 mg/kg (time-course assessment); over 2.5 mg/kg (tonic fits and death prevention)
Administration: i.p.; single dose; 15 minutes prior to seizure challenge (for dose-response); single dose (for time-course assessment)
Result: Achieved an ED50 of 1.1 mg/kg for inhibition of tonic extensor seizures.
Achieved an ED50 of 3.1 mg/kg for inhibition of clonic seizures.
Completely prevented tonic fits and death at doses over 2.5 mg/kg.
Showed more than 80% seizure suppression 3 hours after treatment at 5 mg/kg.
Exhibited strong anticonvulsive effect that gradually disappeared between 3 and 8 hours at 5 mg/kg.
Sustained maximal exit inhibition effect for 4 hours, then gradually decreased to zero between 4 and 8 hours at 5 mg/kg.
Animal Model: NMRI (Crl: NMRI BR-outbread, male, 20-25 g, maximal electroshock seizure model)
Dosage: 2.6 mg/kg
Administration: i.p.; single dose; 30 minutes prior to electroshock
Result: Achieved an ED50 of 2.6 mg/kg for inhibition of tonic hind limb extensor seizures.
Animal Model: NMRI (Crl: NMRI BR-outbread, male, 20-25 g, MgCl2-induced global cerebral ischaemia model)
Dosage: 3.75 mg/kg; 7.5 mg/kg; 15 mg/kg; 30 mg/kg; 8.3 mg/kg (PD50 dose)
Administration: i.p.; single dose; 30 minutes prior to MgCl2 injection
Result: Prolonged survival time in a dose-dependent manner, with a PD50 of 8.3 mg/kg.
Produced significant increases in survival time at doses of 7.5 mg/kg and above.

化学信息

分子量 337.38
分子式 C19H19N3O3
CAS No. 143691-37-6
别名 LY 293606

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础